CANbridge Appoints Acting CMO
This article was originally published in Scrip
CANbridge Life Sciences, a company developing Western drug candidates in North Asia and China, has appointed Mark A. Goldberg acting chief medical officer (CMO) – effective immediately. Previously Goldberg was executive vice-president of medical and regulatory strategy at Synageva BioPharma Corp. Prior to this he was senior vice-president of clinical development and global therapeutic group head, oncology and personalized genetic health at Genzyme Corp.